Olivier Leclercq started his career at the Institut Pasteur in 2005 working on mutation phenomena during somatic hypermutation in the unit of Biochemistry and Genetics of Development, headed by Pr F. Rougeon. In 2009, he joined the unit of Molecular Parasitology and Signaling, head by Dr G. Spaeth, as part of the European FP7 LeishDrug project, to develop a 2D in-gel kinase assay to trace phosphotransferase activity in Leishmania donovani. Then, he was implicated in the PTR 392 “Systems-wide analysis of Leishmania virulence” to investigation genetics, transcriptomics, and proteomics differences between hyper- and hypo-pathogenic L. major field isolates. In 2014, as part of the ANR TransLeish project, Olivier developed a drug target deconvolution approach combining ATP affinity chromatography, competition assays and mass spectrometry to evaluate the specificity and discover the targets of kinase-biased hit compounds. Using this approach, he obtained the first ATPome in trypanosomatids and developed an innovative drug target deconvolution method that can easily be applied to other pathogens or diseases. In 2020, Olivier joined the Signalling and host-parasite interactions group, head by Dr N. Rachidi, to study: (i) the mechanisms of host cell subversion by Leishmania through parasite virulence factors released via extracellular vesicles, and (ii) work on the development of novel anti-leishmanial strategies targeting released parasite virulence factors or host proteins interacting with these virulence factors, to restore the host cell anti-microbial potential (ANR Texleish).
Click to view graph
Connections
Click to view timeline
Timeline
Projects
CV
EDUCATION
- 2016 | EPHE Diploma, Life and Earth Sciences (M2 level), with honors | Ecole Pratique des Hautes Etudes, Paris, France.
- 2003 | Biochemistry Senior technician certificate | High school Uruguay France, Avon, France.
- 2000 | Scientific Baccalaureate, Life and Earth Sciences | General and technological high school Catherine and Raymond Janot, Sens, France.
PROFESSIONAL EXPERIENCE
- 2022 – today | Research Engineer | Unit molecular parasitology and signaling | Pasteur Institute, Paris, France.
- 2011 – 2022 | Senior research technician | Unit molecular parasitology and signaling | Pasteur Institute, Paris, France.
- 2009 – 2011 | Senior research technician | G5 Parasitic virulence | Pasteur Institute, Paris, France.
- 2005 – 2009 | Senior technician | Unit of Biochemistry and Genetics of Development | Pasteur Institute, Paris, France.
- 2004 | Senior technician | French Blood Establishment | Hospital Center, Sens, France.
- 2003 – 2004 | Senior technician | INSERM | Unit 396, Human immunogenetics, Paris, France.
SCIENTIFIC ACTIVITIES
- 10 publications | 1 patent | H-index: 7
- Oral presentations: WorldLeish7: 7th World Congress on Leishmaniasis, Cartagena, Colombia (2022) | Invited speaker (videoconference), Workshop: Genome editing in Leishmania based on CRISPR/Cas9 system, Tehran, Iran (2021) | WorldLeish6: 6th World Congress on Leishmaniasis, Toledo, Spain (2017) | Parasitology and Mycology departmental seminar, Paris, France (2013) | Swiss Trypanosomatid meeting, Lesyn, Switzerland (2010).
- Posters: Future of parasitology, Paris, France (2017) | BSP Autumn Symposium, Microbial protein targets: towards understanding and intervention, Durham, England, (2016) | Trypanosomatid parasites: from the field to the lab. III, Paris, France (2014) | Trypanosomatid parasites: From the Field to the Lab. II, Paris, France (2012) | BSP Spring Meeting including the Trypanosomiasis and Leishmaniasis Seminar, Glasgow, Scotland (2012) | Trypanosomatid parasites: From the Field to the Lab., Paris, France (2011).
SUPERVISING, TRAINING AND TEACHING ACTIVITIES
- RIIP trainees: Ali Ben-Cheikh (PhD), Pasteur Institute of Tunis (3 months, 2021-2022) | Mahmoud Nateghi-Rostami (Dr), Pasteur Institute of Iran (1 month, 2021) | Tahereh Taheri (Dr), Pasteur Institute of Iran (3 months, 2019) | Mingkuan Chen (PhD), Pasteur Institute of Shanghai (3 months, 2015).
- Master/internship: Aicha Stierlen (3 months, 2021-2022) | Paya N’diaye (2 months, 2016) | Jessica Leroux, (2 months, 2010) | Najiha Bilal Farooqi (2 months, 2010).
- Member of the educational project “Pasteur-Banlieues, Scientists of Tomorrow” which allows students of a middle school in the priority education network to discover the world of research (2019 – today)
ADMINISTRATIVE RESPONSIBILITIES AND EXPERTISE
- 2011 – today | Health and Safety correspondent.
- 2022 | Member of the evaluation committee, “Source to pay” call for proposals.
- 2020 – 2021 | Member of the test group, eLab POC.
- 2020 | Member of the evaluation committee, eLab call for proposals.
- 2015 – 2020 | Representative of the College of Technicians of the Parasites and Insect Vectors Department.
Publications
Download-
2021In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition., Eur J Med Chem 2021 Jan; 210(): 112956.
-
2016From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity., Antimicrob Agents Chemother 2016 05; 60(5): 2822-33.
-
2014Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability., PLoS Pathog 2014 Sep; 10(9): e1004347.
-
2014Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses., Mol Microbiol 2014 Jul; 93(1): 146-66.
-
2014Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection., Antimicrob Agents Chemother 2014 ; 58(3): 1501-15.
-
2013Enrichment of Leishmania donovani ATP-binding proteins using a staurosporine capture compound., J Proteomics 2013 Jun; 86(): 97-104.
-
2012The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms., Structure 2012 Oct; 20(10): 1649-60.
-
2011Adaptation of a 2D in-gel kinase assay to trace phosphotransferase activities in the human pathogen Leishmania donovani., J Proteomics 2011 Aug; 74(9): 1644-51.
-
2010Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability., PLoS Negl Trop Dis 2010 Jun; 4(6): e729.
-
2008Ectopic expression of AID in a non-B cell line triggers A:T and G:C point mutations in non-replicating episomal vectors., PLoS One 2008 Jan; 3(1): e1480.
-
+View full list of publications